Sygnature Discovery and Essen BioScience Ltd. form Strategic Alliance
Sygnature Discovery, a company which undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies worldwide, and Essen BioScience Ltd., a world leader in the field of cell-based in vitro assays and instrumentation, today announced they have established into a strategic alliance. Under the terms of the agreement, Sygnature and Essen will collaborate to incorporate Essen’s unique phenotypic assay, live cell imaging and ion channel technologies into Sygnature’s integrated drug discovery projects. This alliance will complement and enhance Essen’s and Sygnature’s contract research capabilities and expertise.
Dr Simon Hirst, Founder and CEO, Sygnature Discovery said, “Essen BioScience has gained a reputation as an innovative company whose groundbreaking inventions have include FLIPR, IonWorks and IncuCyte. These technologies have accelerated countless drug discovery projects. With this new strategic alliance agreement in place, Sygnature and Essen can offer their customers a fully-integrated drug discovery service where novel compounds are designed, synthesised and in vitro tested at Sygnature and assessed at Essen with complementary in vitro techniques. The powerful combination of Essen and Sygnature will speed-up the design-make-test-analyse cycle and thereby advance clients’ drug discovery projects towards development more efficiently.”
Dr Del Trezise, Director and European Site Head for Essen BioScience, commented “Sygnature Discovery are a first class drug discovery partner with outstanding credentials and track record in progressing early and mid-stage projects. Combining Sygnature’s medicinal chemistry and biology-centered discovery platform with Essen’s cutting edge cell-based assay solutions will provide our clients with best-in-class integrated solutions for outsourced projects.”